Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
SANA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $7.30
Previous CloseN/A
Volume118.31M
Average Volume (3M)3.91M
Market Cap
$1.15B
Enterprise Value$659.48M
Total Cash (Recent Filing)$72.67M
Total Debt (Recent Filing)$85.49M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 05, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding258,702,030
10 Day Avg. Volume3,601,425
30 Day Avg. Volume3,905,717
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue43.15
Enterprise Value/Gross Profit907.12
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$8.25Price Target Upside90.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial StabilitySana enters the second half of the year in a well-capitalized position to execute its program development goals after raises that accumulated approximately $105M.
Regulatory ProgressThe positive feedback from the FDA INTERACT meeting substantially raises the probability of success for the company's program.
Technological AdvancementsSana Biotechnology's platforms for immune evasion and in vivo CAR-T hold substantial long-term growth potential.
Bears Say
Financial PerformanceSana reported a GAAP net loss of $93.8MM for the second quarter.
Market ChallengesSC451 represents a substantial market opportunity for Sana as obtaining donor-derived islet cells at scale is very challenging, while iPSC-derived cells like SC451 can be expanded indefinitely.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.26 and its highest was $7.30 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $1.15B.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Nov 05, 2025 which is in 25 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Aug 11, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.201 by -$0.189.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.19.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 258,702,030 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.201. Following the earnings report the stock price went up 6.507%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
Sana Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (90.97% Upside)
$8.25 (90.97% Upside)
Blogger Sentiment
Bullish
SANA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 566.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.79%
12-Months-Change
Fundamentals
Return on Equity
-109.12%
Trailing 12-Months
Asset Growth
-41.54%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$8.25
▲(90.97% Upside)
Technical Analysis
Geron
―
Relay Therapeutics
―
Taysha Gene Therapies
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
29.26% Insiders
12.47% Mutual Funds
24.31% Other Institutional Investors
28.29% Public Companies and
Individual Investors